P
Powel H. Brown
Researcher at University of Texas at Austin
Publications - 96
Citations - 4945
Powel H. Brown is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 39, co-authored 96 publications receiving 4694 citations. Previous affiliations of Powel H. Brown include University of Texas at San Antonio & Uniformed Services University of the Health Sciences.
Papers
More filters
Journal ArticleDOI
Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8
Zachary C. Hartman,Graham M. Poage,Petra den Hollander,Anna Tsimelzon,Jamal Hill,Nattapon Panupinthu,Yun Zhang,Abhijit Mazumdar,Susan G. Hilsenbeck,Gordon B. Mills,Powel H. Brown +10 more
TL;DR: A Cox multivariable analysis of patient specimens revealed that IL-6 and IL-8 expression predicted patient survival times, offering a rationale for dual inhibition of IL- 6/IL-8 signaling as a therapeutic strategy to improve outcomes for patients with TNBCs.
Journal ArticleDOI
Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline
Kala Visvanathan,Patricia Hurley,Elissa T. Bantug,Powel H. Brown,Nananda F. Col,Jack Cuzick,Nancy E. Davidson,Andrea Decensi,Carol J. Fabian,Leslie G. Ford,Judy Garber,Maria C. Katapodi,Barnett S. Kramer,Monica Morrow,Barbara A. Parker,Carolyn D. Runowicz,Victor G. Vogel,James L. Wade,Scott M. Lippman +18 more
TL;DR: A systematic review of randomized controlled trials and meta-analyses published from June 2007 through June 2012 found six chemoprevention agents were identified and tamoxifen should be discussed as an option to reduce the risk of estrogen receptor -positive BC.
Journal ArticleDOI
American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
Kala Visvanathan,Rowan T. Chlebowski,Patricia Hurley,Nananda F. Col,Mary E. Ropka,Deborah Collyar,Monica Morrow,Carolyn D. Runowicz,Kathleen I. Pritchard,Karen L. Hagerty,Banu Arun,Judy Garber,Victor G. Vogel,James L. Wade,Powel H. Brown,Jack Cuzick,Barnett S. Kramer,Scott M. Lippman +17 more
TL;DR: An expert panel reviewed the literature and developed updated consensus guidelines on pharmacologic interventions for breast cancer risk reduction, finding no evidence exists establishing whether a reduction in BC risk from either agent translates into reduced BC mortality.
Journal Article
Mechanism of action of a dominant-negative mutant of c-Jun.
TL;DR: The results suggest that TAM-67 inhibits AP-1-mediated processes through a 'quenching' mechanism by inhibiting the function of endogenous Jun and/or Fos proteins.
Journal ArticleDOI
cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype.
Leia M. Smith,Scott C. Wise,Scott C. Wise,Denver T. Hendricks,Anita L. Sabichi,Timothy J. Bos,Praveen Reddy,Powel H. Brown,Michael J. Birrer +8 more
TL;DR: Overexpression of Jun causes significant alterations in the composition of AP-1, decreased junB and increased fra-1 expression and results in an increased biologic aggressiveness, which mimic those seen clinically in breast cancer.